Acton Pharmaceuticals, Inc. Announces Completion of $15 Million Series A Financing with Sequoia Capital
Acton has licensed AEROSPAN™ (flunisolide HFA, 80 mcg) Inhalation Aerosol from Forest Laboratories, Inc. which will compete in the $7 billion inhaled steroid market
MARLBOROUGH, Mass., January 6, 2010– Acton Pharmaceuticals, Inc. (Acton) today announced completion of a $15 million round of financing led by Sequoia Capital. Acton also announced today that it has completed a [...]
